Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

162 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Phase 2a cohort expansion study to assess the safety, tolerability, and preliminary efficacy of CXD101 in patients with advanced solid-organ cancer expressing HR23B or lymphoma.
Booth SW, Eyre TA, Whittaker J, Campo L, Wang LM, Soilleux E, Royston D, Rees G, Kesavan M, Hildyard C, Kazmi F, La Thangue N, Kerr D, Middleton MR, Collins GP. Booth SW, et al. Among authors: la thangue n. BMC Cancer. 2021 Jul 23;21(1):851. doi: 10.1186/s12885-021-08595-w. BMC Cancer. 2021. PMID: 34301221 Free PMC article. Clinical Trial.
HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy.
Khan O, Fotheringham S, Wood V, Stimson L, Zhang C, Pezzella F, Duvic M, Kerr DJ, La Thangue NB. Khan O, et al. Proc Natl Acad Sci U S A. 2010 Apr 6;107(14):6532-7. doi: 10.1073/pnas.0913912107. Epub 2010 Mar 22. Proc Natl Acad Sci U S A. 2010. PMID: 20308564 Free PMC article.
A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancer.
Eyre TA, Collins GP, Gupta A, Coupe N, Sheikh S, Whittaker J, Wang LM, Campo L, Soilleux E, Tysoe F, Cousins R, La Thangue N, Folkes LK, Stratford MRL, Kerr D, Middleton MR. Eyre TA, et al. Among authors: la thangue n. Cancer. 2019 Jan 1;125(1):99-108. doi: 10.1002/cncr.31791. Epub 2018 Oct 17. Cancer. 2019. PMID: 30332497 Free article. Clinical Trial.
Immune modulation underpins the anti-cancer activity of HDAC inhibitors.
Blaszczak W, Liu G, Zhu H, Barczak W, Shrestha A, Albayrak G, Zheng S, Kerr D, Samsonova A, La Thangue NB. Blaszczak W, et al. Among authors: la thangue nb. Mol Oncol. 2021 Dec;15(12):3280-3298. doi: 10.1002/1878-0261.12953. Epub 2021 May 1. Mol Oncol. 2021. PMID: 33773029 Free PMC article.
162 results